^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-7R antagonist

    Related drugs:
    1m
    A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (clinicaltrials.gov)
    P2, N=75, Active, not recruiting, Q32 Bio Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    6ms
    CoTikiS: Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis (clinicaltrials.gov)
    P2, N=136, Completed, OSE Immunotherapeutics | Recruiting --> Completed | Trial completion date: Mar 2023 --> Jan 2025
    Trial completion • Trial completion date
    |
    lusvertikimab (OSE-127)
    8ms
    A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (clinicaltrials.gov)
    P2, N=75, Recruiting, Q32 Bio Inc. | Active, not recruiting --> Recruiting | N=40 --> 75 | Trial completion date: Dec 2024 --> Sep 2026 | Trial primary completion date: Dec 2024 --> Jun 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    1year
    Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, Q32 Bio Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    over1year
    SIGNAL-AA: Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Q32 Bio Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    over1year
    Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients (clinicaltrials.gov)
    P2, N=48, Completed, Institut de Recherches Internationales Servier | Phase classification: P2a --> P2
    Phase classification
    |
    lusvertikimab (OSE-127)
    over1year
    The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis. (PubMed, Blood)
    Lusvertikimab-mediated in vitro ADCP levels significantly correlated with CD127 expression levels and the reduction of leukemia burden upon treatment of PDX animals in vivo. Altogether, through its dual mode of action and good safety profile, Lusvertikimab may represent a novel immunotherapy option for any CD127-positive ALL, particularly in combination with standard-of-care polychemotherapy.
    Journal • IO biomarker
    |
    IL7R (Interleukin 7 Receptor) • IL7 (Interleukin 7)
    |
    IL7R expression
    |
    lusvertikimab (OSE-127)
    almost2years
    Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (clinicaltrials.gov)
    P2, N=102, Recruiting, Q32 Bio Inc. | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    almost2years
    SIGNAL-AA: Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata (clinicaltrials.gov)
    P2, N=40, Recruiting, Q32 Bio Inc. | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    almost2years
    SIGNAL-AA: Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata (clinicaltrials.gov)
    P2, N=40, Recruiting, Q32 Bio Inc.
    Trial completion date • Trial primary completion date
    2years
    SIGNAL-AA: Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata (clinicaltrials.gov)
    P2, N=40, Recruiting, Q32 Bio Inc. | Phase classification: P2a --> P2
    Phase classification
    2years
    Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (clinicaltrials.gov)
    P2, N=102, Recruiting, Q32 Bio Inc. | Phase classification: P2a --> P2
    Phase classification